Lessons learned in shaping vaccine markets in low-income countries: A review of the vaccine market segment supported by the GAVI Alliance

Health Policy and Planning

Volumn 28, Issue 8, 2013, Pages 838-846

  Gilchrist, Shawn A N ^a   Nanni, Angeline ^b  

^a President S Gilchrist Consulting Services Inc   (Canada)

^b AERAS   (United States)

Author keywords

Developing country vaccine market; donor assistance policies; economics of vaccines; global immunization policy; new vaccine introduction strategies

Indexed keywords

VACCINE;

COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; ECONOMIC ASPECT; ECONOMICS; INTERNATIONAL COOPERATION; SUPPLY AND DISTRIBUTION;

COMMERCE; DEVELOPING COUNTRIES; ECONOMIC COMPETITION; INTERNATIONAL COOPERATION; VACCINES;

EID: 84890475801     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czs123     Document Type: Review

References (52)

1. Arie S. 2011. How should GAVI build on its success BMJ 343: d5182.
2. Batson A. 2001. Understanding the Vaccine Market and Its Economics-Obstacles and Potential Solutions-Presentation to the Out of Box Group. http://fr.gavialliance.org/resources/21VacMarket.pdf, accessed 13 January 2012.
3. Batson A, Evans P, Milstien JB. 1994. The crisis in vaccine supply: a framework for action. Vaccine 12: 963-5.
4. Bloom DE, Canning D, Weston M. 2005. The value of vaccination. World Economics 6: 15-39.
5. CEPA LLP, Applied Strategies. 2010. Second GAVI Evaluation Report. http://www.gavialliance.org/results/evaluations/gavi-second-evaluationreport/, accessed 13 January 2012.
6. Chandran A, Watt JP, Santosham M. 2008. Haemophilus influenzae vaccines. In: Plotkin S, Orenstein W, Offit P (eds). Vaccines. 5th edn. China: Saunders Elsevier, 157-77.
7. Chee G, Molldrem V, Hsi N, Chankova S. 2008. Evaluation of the GAVI Phase 1 Performance. Bethesda, MD: Abt Associates Inc. http://www. gavialliance.org/results/evaluations/gavi-first-evaluation-report/, accessed 13 January 2012.
8. Cornejo S, Schwalbe N, Tanguy N. 2011. Building Country Ownership and Sustainability: Country Co-financing of Vaccines. The GAVI Alliance White Paper. http://www.gavialliance.org/library/gavi-documents/whitepapers/building- ownership-and-sustainability-country-co-financing-of-vaccines/, accessed 13 January 2011.
9. Decker MD, Edwards KM, Bogaerts HH. 2008. Combination vaccines. In: Plotkin S, Orenstein W, Offit P (eds). Vaccines. 5th edn. China: Saunders Elsevier, pp. 1069-101.
10. DeRoeck D. 2002. Immunization Financing in Developing Countries and the International Vaccine Market Trends and Issues. Manila, Philippines: Asian Development Bank.
11. Ellis RW. 1999. Combination Vaccines: Development, Clinical Research, and Approval. Totowa, NJ: Humana Press Inc.
12. GAVI Alliance. 2001. Fifth GAVI Board Meeting-Sustainable Immunization Services-Status Report on Development Guidelines for Countries. http://fr. gavialliance.org/about/governance/boards/reports/5th-Board-fifth-boardmeeting. php, accessed 12 January 2012.
13. GAVI Alliance. 2009. Update: GAVI Partners Fulfill Promise to Fight Pneumococcal Disease. Advanced Market Commitments for Vaccines. http://www.gavialliance.org/funding/pneumococcal-amc/, accessed 12 January 2012.
14. GAVI Alliance. 2010. Key Indicators: Measuring the Alliance's Progress Against its Four Strategic Goals. http://fr.gavialliance.org/performance/global- results/GAVI-Alliance-Results-2008-Market-supply.php, accessed 13 January 2012.
15. GAVI Alliance. 2011a. Donors Commit Vaccine Funding to Achieve Historic Milestone in Global Health. http://fr.gavialliance.org/resources/GAVI-Pledging- Conference-PR-and-Key-Outcomes-June-2011.pdf, accessed 13 December 2011.
16. GAVI Alliance. 2011b. FAQs. Questions and Answers about the GAVI Alliance. http://fr.gavialliance.org/media-centre/faqs/index.php, accessed 12 January 2012.
17. GAVI Alliance. 2012a. Phase I (2000-2006)
18. GAVI's First Five-Years Focused on Getting Funds to Countries Quickly to Extend the Reach and Quality of Immunisation Programmes. http://www. gavialliance.org/about/strat egy/phase-i-(2000-06)/, accessed 13 January 2012.
19. GAVI Alliance. 2012b. Phase II (2007-10). Period of Significant Innovation and Changes. http://www.gavialliance.org/about/strategy/phase-ii- (2007-10)/, accessed 13 January 2012.
20. GAVI Alliance. 2012c. Phase III (2011-2015). In 2010, the GAVI Alliance Board Approved a Second Five-Year Strategy to Support its Mission and a Business Plan to Guide Implementation. http://www.gavialliance.org/about/strategy/phase- iii-(2011-15)/, accessed 13 January 2012.
21. GAVI Alliance. 2012d. GAVI's Business Model. Accelerated Vaccine Introduction Initiative. The Accelerated Vaccine Introduction Initiative is at the Heart of the GAVI Business Model. http://www.gavialliance.org/about/gavis- business-model/avi/, accessed 13 January 2012
22. GlaxoSmithKline. 2010. GlaxoSmithKline Statement on New Information Relating to Manufacture of Rotarix (Rotavirus Vaccine). London. http://www.gsk.com/media/pressreleases/2010/2010-pressrelease-10029. htm, accessed 12 January 2012.
23. GlaxoSmithKline Biologicals. 2009. Addressing Developing World Vaccine Production Technology Transfer. Global Vaccines Public Policy Issues. http://www.gsk.com/policies/Technology-Transfer-Vaccines.pdf, accessed 12 January 2012.
24. Godal T. 2000. Viewpoint: immunization against poverty. Tropical Medicine and International Health 5: 160-6.
25. Greco M. 2004. Development and supply of vaccines: an industry perspective. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (eds). New Generation Vaccines. 3rd edn. NY: Marcel Dekker Inc.
26. Institute of Medicine. 1993. Chapter 4-vaccine demand and supply. The Children's Vaccine Initiative: Achieving The Vision. Washington, DC: National Academies Press. http://www.nap.edu/openbook.php record-id2224&page66, accessed 13 January 2012.
27. Institute of Medicine. 2004. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press
28. International Financial Facility for Immunization. 2011. Supporting GAVI. http://www.iffim.org/about/overview/, accessed 12 January 2012.
29. Kim-Farley R. 1992. Global Immunization. Annual Review of Public Health 13: 223-37.
30. Lydon P, Beyai PL, Chaudhri I et al. 2008. Government financing for health and specific national budget lines: the case of vaccines and immunization. Vaccine 26: 6727-34.
31. Marwick C. 1996. Switch to inactivated polio vaccine recommended. JAMA 276: 89.
32. Mast EE, Ward JW. 2008. Hepatitis B vaccines. In: Plotkin S, Orenstein W, Offit P (eds). Vaccines. 5th edn. China: Saunders Elsevier, pp. 205-41.
33. Milstien JB, Batson A, Wertheimer AI. 2005. Vaccines and Drugs: Characteristics of Their Use to Meet Public Health Goals. Washington, DC: Health Nutrition and Population, The World Bank. http://siter esources.worldbank.org/ HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/ MilstienVaccinesDrugsFinal.pdf, accessed 13 January 2012.
34. Milstien JB, Gaule P, Kaddar M. 2007. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 25: 7610-9.
35. Plotkin SL, Plotkin SA. 2008. A short history of vaccination. In: Plotkin S, Orenstein W, Offit P (eds). Vaccines. 5th edn. China: Saunders Elsevier, 5.
36. Pneumo ADIP, Applied Strategies. 2009. Strategic Demand Forecast History 2003-2008. Baltimore, MD. http://preventpneumo.org/vaccine/sup ply/loader.cfmcsModulesecurity/getfile&pageid4892, accessed 13 January 2012.
37. Sekhri N. 2006. Forecasting for Global Health: New Money, New Products and New Markets. Background Paper for the Forecasting Working Group. Washington, DC: Center for Global Development. http://www. cgdev.org/doc/ghprn/Forecasting- Background.pdf, accessed 13 January 2012
38. Serum Institute of India Ltd. 2011. Milestones. http://www. seruminstitute. com/content/news-mile.htm, accessed 12 January 2012.
39. UNICEF. 2011a. Product Menu for Vaccines Supplied by UNICEF for the GAVI Alliance. UNICEF Supply and Logistics. http://www.unicef.org/supply/files/ Product-Menu-June-2011.pdf, accessed 13 January 2012.
40. UNICEF. 2011b. Supply and Logistics. GAVI. DTP-HepB-Hib 2001-2010. http://www.unicef.org/supply/files/11-05-23-DTP-HepB-Hib.pdf, accessed 13 January 2012.
41. UNICEF. 2011c. Supplies and Logistics. Vaccine price data. HepB. http://www. unicef.org/videoaudio/PDFs/11-06-03-HepB.pdf, accessed 13 January 2012.
42. UNICEF. 2011d. Supplies and Logistics. Vaccine Price Data. Yellow Fever. http://www.unicef.org/videoaudio/PDFs/11-06-03-HepB.pdf, accessed 13 January 2012.
43. UNICEF. 2011e. Potential Benefits, Challenges and Risks of Improved Vaccine Pricing Transparency. UNICEF's Views and Suggestions. http://www. technet21.org/index.php/tools/view-document/1157-potentialbenefits-challenges- and-risks-of-improved-vaccine-pricingtransparency.html, accessed 12 January 2012.
44. UNICEF. 2011f. Vaccine Price Data. UNICEF Supply and Logistics. http://www.unicef.org/supply/index-57476.html, accessed 12 January 2012
45. United Kingdom Department for International Development. 2011. Multilateral Aid Review Ensuring Maximum Value for Money for UK Aid Through Multilateral Organisations. http://www.dfid.gov.uk/Docu ments/publications1/mar/ multilateral-aid-review.pdf, accessed 13 January 2012
46. United States Centers for Disease Control and Prevention. 1997. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the advisory committee on immunization practices (ACIP). MMWR 46: 1-25
47. United States Centers for Disease Control and Prevention. 2011. Pediatric/VFC Vaccine Price List. CDC Vaccine Price List. http://www. cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm, accessed 12 January 2012.
48. Whitehead P, Pasternak A. 2002. Lessons Learned: New Procurement Strategies for Vaccines. Final Report to the GAVI Board. Mercer Management Consulting. http://fr.gavialliance.org/resources/Mercer-lessons-draft-final.pdf, accessed 13 December 2011.
49. Wilson P. 2010. Giving Developing Countries Their Best Shot: An Overview of Vaccine Access and R&D. Campaign for Access to Medicines, Medecins sans frontiers. Geneva, Switzerland: Oxfam and Campaign for Access to Essential Medicines. http://www.oxfam.org/sites/www.oxfam.org/files/giving-developing- countries-best-shot-vaccines-2010-05.pdf, accessed 13 January 2012.
50. World Health Organization, UNICEF. 1996. State of the World's Vaccines and Immunizations. Geneva. http://whqlibdoc.who.int/hq/1996/WHO-GPV-96.04.pdf, accessed 13 December 2011.
51. World Health Organization, UNICEF, World Bank. 2009. State of the World's Vaccines and Immunization. 3rd edn. Geneva: World Health Organization. http://www.unicef.org/immunization/files/SOWVI-full-report-english-LR1.pdf, accessed 13 January 2012.
52. Wrobel S. 2007. Developing Country Demand Forecasting: An Evolving Perspective. Presentation at World Vaccine Congress. http://www.applied strategies.com/News/WVC-DemandForecasting-Wrobel-19Mar07. pdf, accessed 13 January 2012.